Equities Analysts Offer Predictions for MNPR FY2025 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at Chardan Capital issued their FY2025 EPS estimates for shares of Monopar Therapeutics in a research report issued on Tuesday, June 24th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings per share of ($2.02) for the year. Chardan Capital currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($2.87) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.27.

Several other equities research analysts have also issued reports on MNPR. Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Piper Sandler restated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $56.50.

Monopar Therapeutics Stock Down 4.0%

Shares of NASDAQ:MNPR opened at $33.60 on Friday. Monopar Therapeutics has a 52 week low of $1.72 and a 52 week high of $54.30. The stock has a market capitalization of $205.63 million, a P/E ratio of -9.66 and a beta of 0.99. The firm has a fifty day simple moving average of $36.75 and a two-hundred day simple moving average of $34.76.

Insider Activity at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC bought a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $44,000. JPMorgan Chase & Co. bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $45,000. Gerber LLC bought a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $204,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $377,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.